Macrophage migration inhibitory factor promotes colorectal cancer

Molecular Medicine

Volumn 15, Issue 1-2, 2009, Pages 1-10

  He, Xing Xiang ^a   Chen, Ken ^a   Yang, Jun ^b   Li, Xiao Yu ^c   Gan, Huo Ye ^c   Liu, Cheng Yong ^c   Coleman, Thomas R ^d   Al Abed, Yousef ^d,e  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; MACROPHAGE MIGRATION INHIBITION FACTOR; VASCULOTROPIN; 3 (4 HYDROXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLEACETIC ACID METHYL ESTER; 3-(4-HYDROXYPHENYL)-4,5-DIHYDRO-5-ISOXAZOLEACETIC ACID METHYL ESTER; ISOXAZOLE DERIVATIVE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL LINE; CELL TRANSPLANTATION; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CANCER INVASION; CANCER STAGING; CANCER TRANSPLANTATION; COLORECTAL TUMOR; DISEASE MODEL; DRUG ANTAGONISM; LIVER TUMOR; METABOLISM; METASTASIS; RISK FACTOR; STATISTICS; TUMOR CELL CULTURE;

ANIMALS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; ISOXAZOLES; LIVER NEOPLASMS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASM TRANSPLANTATION; RISK FACTORS; STATISTICS AS TOPIC; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 59649119604     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2008.00107     Document Type: Article

References (54)

1. Boyle P, Ferlay J. (2005) Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16:481-488.
2. American Cancer Society. (2006) Cancer facts and figures, 2005. Atlanta, GA: American Cancer Society.
3. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. (2002) Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect. 4:449-460.
4. Mitchell RA, et al. (2002) Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. U. S. A. 99:345-350.
5. White ES, et al. (2003) Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin. Cancer Res. 9:853-860.
6. Takahashi N, et al. (1998) Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol. Med. 4:707-714.
7. Chesney J, et al. (1999) An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol. Med. 5:181-191.
8. Yang Y, Degranpre P, Kharfi A, Akoum A. (2000) Identification of macrophage migration inhibitory factor as a potent endothelial cell growth-promoting agent released by ectopic human endometrial cells. J. Clin. Endocrinol. Metab 85:4721-4727.
9. Ogawa H, et al. (2000) An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine 12:309-314.
10. Sun B, et al. (2005) Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res. 11:1050-1058.
11. Hudson JD, et al. (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190:1375-1382.
12. Meyer-Siegler K, Hudson PB. (1996) Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 48:448-452.
13. Bini L, et al. (1997) Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 18:2832-2841.
14. Ren Y, et al. (2003) Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int. J. Cancer 107:22-29.
15. Kamimura A, et al. (2000) Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 89:334-341.
16. Ren Y, et al. (2005) Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg 242:55-63.
17. Li Z, et al. (2004) Macrophage migration inhibitory factor enhances neoplastic cell invasion by inducing the expression of matrix metalloproteinase 9 and interleukin-8 in nasopharyngeal carcinoma cell lines. Chin Med. J. (Engl.) 117:107-114.
18. Dios A, et al. (2002) Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J. Med. Chem. 45:2410-2416.
19. Al-Abed Y, et al. (2005) ISO-1 binding to the tautomerase active site of MIF inhibits its proinflammatory activity and increases survival in severe sepsis. J. Biol. Chem. 280:36541-36544.
20. Lubetsky JB, et al. (2002) The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. 277:24976-24982.
21. Cvetkovic I, et al. (2005) Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 146:2942-2951.
22. Nemajerova A, Moll UM, Petrenko O, Fingerle-Rowson G. (2007) Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycle. Cell Cycle (Georgetown, Tex.) 6:1030-1034.
23. Ohkawara T, et al. (2005) Transgenic over-expression of macrophage migration inhibitory factor renders mice markedly more susceptible to experimental colitis. Clin. Exp. Immunol. 140:241-248.
24. Nicoletti F, et al. (2005) Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barre syndrome and experimental allergic neuritis. J. Neuroimmunol. 168:168-174.
25. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. (2006) Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J. Immunol. 177:8730-8739.
26. Rendon BE, et al. (2007) Regulation of human lung adenocarcinoma cell migration and invasion by MIF. J Biol. Chem. 282:29910-29918.
27. Sakuragi T, et al. (2007) Lung-derived macrophage migration inhibitory factor in sepsis induces cardio-circulatory depression. Surg. Infect. (Larchmt) 8:29-40.
28. Calandra T, Roger T. (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. Immunol. 3:791-800.
29. Flaster H, Bernhagen J, Calandra T, Bucala R. (2007) The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol. Endocrinol. 21:1267-1280.
30. Shun CT, Lin JT, Huang SP, Lin MT, Wu MS. (2005) Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas. World J. Gastroenterol. 11:3767-3771.
31. Sun B, et al. (2003) Induction of macrophage migration inhibitory factor by lysophosphatidic acid: relevance to tumor growth and angiogenesis. Int. J. Mol. Med. 12:633-641.
32. Wilson JM, et al. (2005) Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 129:1485-1503.
33. Werner JA, Rathcke IO, Mandic R. (2002) The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin. Exp. Metastasis 19:275-282.
34. Zeng ZS, Cohen AM, Guillem JG. (1999) Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 20:749-755.
35. Heslin MJ, et al. (2001) Role of matrix metalloproteinases in colorectal carcinogenesis. Ann. Surg. 233:786-792.
36. Moran A, et al. (2005) Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol. Rep. 13:115-120.
37. Li BH, et al. (2005) Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis. World J. Gastroenterol. 11:3046-3050.
38. Curran S, et al. (2004) Matrix metalloproteinase/ tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin. Cancer Res. 10:8229-8234.
39. Ogata Y, et al. (2006) The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Cancer Chemother. Pharmacol. 57:577-583.
40. Chen X, et al. (2005) Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells. Int. J. Cancer 116:52-61.
41. Meyer E, Vollmer JY, Bovey R, Stamenkovic I. (2005) Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis. Cancer Res. 65:4261-4272.
42. Hagemann T, et al. (2005) Macrophages induce invasiveness of epithelial cancer cells via NFkappa B and JNK. J. Immunol. 175:1197-1205.
43. Onodera S, et al. (2002) Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts: relevance to intracellular signaling pathways. J. Biol. Chem. 277:7865-7874.
44. Plate KH, Breier G, Weich HA, Risau W. (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-848.
45. Nakasaki T, et al. (2002) Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am. J. Hematol. 69:247-254.
46. Kondo Y, et al. (2000) Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma. Cancer 88:1820-1827.
47. Nanashima A, et al. (1998) Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers. Dig. Dis. Sci. 43:2634-2640.
48. Kondo Y, et al. (2000) Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line. Clin. Cancer Res. 6:622-630.
49. Ishigami SI, et al. (1998) Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer 78:1379-1384.
50. Landriscina M, et al. (1998) Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br. J. Cancer 78:765-770.
51. Kumar H, et al. (1998) Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin. Cancer Res. 4:1279-1285.
52. Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K, Tanikawa K. (1998) Circulating vascular endothelial growth factor in patients with colorectal cancer. Am. J. Gastroenterol. 93:249-252.
53. Calvani M, Trisciuoglio D, Bergamaschi C, Shoemaker RH, Melillo G, et al. (2008) Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res. 68:285-91.
54. Zaman K, et al. (2006) Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. Int. J. Cancer 118:755-764.